- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04368403
A Study of KHK4827 in Patients With Systemic Sclerosis
February 13, 2023 updated by: Kyowa Kirin Co., Ltd.
A Phase 1, Open-label, Multiple-dose Study of KHK4827 in Subjects With Systemic Sclerosis
Exploratory evaluation of pharmacokinetics and safety of KHK4827 in subjects with systemic sclerosis
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8655
- The University of Tokyo Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject meets the criteria for diagnosis of the Diagnostic Criteria, Severity Classification, and Clinical Practice Guidelines for Systemic Sclerosis (Japanese Dermatological Association 2016) at the pre-examination
- Subject presented the first symptoms of sclerosis other than Raynaud's phenomenon within 60 months before enrollment
- Subject who has systemic sclerosis accompanied by moderate to severe skin thickening with an mRSS of 10 to <30 at the pre-examination and who has progressing skin thickening
Exclusion Criteria:
Any of the following significant concomitant diseases:
- Type 1 diabetes
- Poorly controlled type 2 diabetes (HbA1c > 8.5%)
- Congestive heart failure (Class II to IV of the New York Heart Association Functional Classification)
- Myocardial infarction, unstable angina, or stroke occurring within 12 months before the first dose of investigational product
- Poorly controlled hypertension (systolic pressure > 150 mm Hg or diastolic pressure > 90 mg Hg at screening)
- Severe chronic lung disease (%Forced Vital Capacity (FVC) < 60% and %Diffusing capacity of lung for carbon monoxide (DLco) < 40%, calculated according to the Reference Values for Spirometry, Including Viral Capacity, in Japanese Adults Calculated with the LMS Method and Compared with Previous Values [Japanese Respiratory Society])
- Major chronic inflammatory diseases or connective tissue diseases other than scleroderma
- Patient has a history or evidence of a psychiatric disorder, alcohol and/or substance abuse, or any other mental health disorder that, in the opinion of the investigators, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
- Patient has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at enrollment
- Patient has severe depression based on a total score of ≥ 15 on the Patient Health Questionnaire-8 (PHQ-8) at enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KHK4827
|
210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
serum KHK4827 concentration
Time Frame: Pre-dose, Week 1, 2, 4, 8, 12, 16, 22, 24, 36, 48, 52 and every 24 weeks through study completion until 2023.
|
Pre-dose, Week 1, 2, 4, 8, 12, 16, 22, 24, 36, 48, 52 and every 24 weeks through study completion until 2023.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in modified Rodnan skin score (mRSS) from baseline
Time Frame: Pre-dose, Week 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and every 8 weeks through study completion until 2023.
|
mRSS: scored 0(normal), 1(mild), 2(moderate), or 3(severe) per each site, assessed in 17 different body sites, total score=51
|
Pre-dose, Week 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and every 8 weeks through study completion until 2023.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 6, 2017
Primary Completion (ACTUAL)
January 31, 2019
Study Completion (ANTICIPATED)
February 29, 2024
Study Registration Dates
First Submitted
April 13, 2020
First Submitted That Met QC Criteria
April 28, 2020
First Posted (ACTUAL)
April 29, 2020
Study Record Updates
Last Update Posted (ESTIMATE)
February 14, 2023
Last Update Submitted That Met QC Criteria
February 13, 2023
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4827-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
Clinical Trials on KHK4827
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin China Pharmaceutical Co., LTD.WithdrawnModerate to Severe Plaque PsoriasisChina
-
Kyowa Kirin Co., Ltd.CompletedPsoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic ErythrodermaJapan
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.CompletedAxial SpondyloarthritisKorea, Republic of, Taiwan, Japan
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Active, not recruitingModerate to Severe Systemic SclerosisJapan
-
Kyowa Kirin Korea Co., Ltd.CompletedModerate to Severe Plaque PsoriasisKorea, Republic of